Retatrutide 20mg

The triple agonist of controversy to the point of political lobbying

Its one of the most discussed compounds in metabolic research over the last two years, and our best-selling line.

Retatrutide research literature suggests that it targets GLP-1, GIP and glucagon receptors simultaneously, making it mechanistically distinct from earlier single-agonist compounds. It is the subject of significant ongoing clinical and pre-clinical research across multiple areas.

Research has examined Retatrutide in the context of:

• GLP-1 receptor pathway activation and appetite-regulation models
• GIP receptor modulation and metabolic balance
• Glucagon receptor effects on energy expenditure
• Adiposity and body composition research models
• Lipid metabolism and cardiometabolic risk factor studies

20mg per vial. The published literature is unusually strong for a compound still in active development, which is why it is so widely studied.

Supplied: Lyophilised powder, ≥99% purity, third-party tested. CoA available on request.
Storage: Refrigerate at 2–8°C. Reconstitute with bacteriostatic water. Use within 45 days of reconstitution.
For research use only. Not for human or veterinary consumption. Not intended to diagnose, treat, cure or prevent any disease. Not for sale to minors.